LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article ; Online: Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience.

    Meziyerh, Soufian / van der Helm, Danny / de Vries, Aiko P J

    Transplant international : official journal of the European Society for Organ Transplantation

    2020  Volume 33, Issue 11, Page(s) 1557–1561

    MeSH term(s) Adult ; Aged ; COVID-19/etiology ; COVID-19/mortality ; COVID-19/therapy ; Case-Control Studies ; Female ; Humans ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/surgery ; Kidney Transplantation ; Male ; Middle Aged ; Postoperative Complications/mortality ; Postoperative Complications/therapy ; Risk Factors ; Survival Analysis ; United States/epidemiology
    Keywords covid19
    Language English
    Publishing date 2020-08-26
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.1111/tri.13714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Vulnerabilities in kidney transplant recipients with COVID‐19

    Meziyerh, Soufian / Helm, Danny / Vries, Aiko P. J.

    Transplant International ; ISSN 0934-0874 1432-2277

    a single center experience

    2020  

    Keywords Transplantation ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    DOI 10.1111/tri.13714
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsy-Proven Acute Rejection: A Study to Provide Evidence for Longer-Term Target Ranges.

    Meziyerh, Soufian / van Gelder, Teun / Kers, Jesper / van der Helm, Danny / van der Boog, Paul J M / de Fijter, Johan W / Moes, Dirk Jan A R / de Vries, Aiko P J

    Clinical pharmacology and therapeutics

    2023  Volume 114, Issue 1, Page(s) 192–200

    Abstract: Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac- ... ...

    Abstract Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac-trough levels (C
    MeSH term(s) Humans ; Tacrolimus/adverse effects ; Mycophenolic Acid/adverse effects ; Immunosuppressive Agents/adverse effects ; Kidney Transplantation/adverse effects ; Graft Rejection/prevention & control
    Chemical Substances Tacrolimus (WM0HAQ4WNM) ; Mycophenolic Acid (HU9DX48N0T) ; Immunosuppressive Agents
    Language English
    Publishing date 2023-05-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Meltdose Tacrolimus Population Pharmacokinetics and Limited Sampling Strategy Evaluation in Elderly Kidney Transplant Recipients.

    Kamp, Jasper / Zwart, Tom C / Meziyerh, Soufian / van der Boog, Paul J M / Nijgh, Esther E / van Duin, Koen / de Vries, Aiko P J / Moes, Dirk Jan A R

    Pharmaceutics

    2023  Volume 16, Issue 1

    Abstract: Background: Meltdose tacrolimus (Envarsus: Methods: A total of 34 kidney transplant recipients aged ≥65 years, starting on meltdose tacrolimus directly after transplantation, were included. An eight-point whole blood AUC: Results: The PK data were ...

    Abstract Background: Meltdose tacrolimus (Envarsus
    Methods: A total of 34 kidney transplant recipients aged ≥65 years, starting on meltdose tacrolimus directly after transplantation, were included. An eight-point whole blood AUC
    Results: The PK data were best described using a two-compartment model, including three transit compartments and a mixture model for oral absorption. The best three-sample LSS was T = 0, 2, 6 h. The best four-sample LSSs were T = 0, 2, 6, 8 h and T = 0, 1, 6, 8 h.
    Conclusions: The developed population PK model adequately described the tacrolimus PK data in a population of elderly kidney transplant recipients. In addition, the developed population PK model and LSS showed an adequate estimation of tacrolimus exposure, and may therefore be used to aid in tacrolimus dose individualization.
    Language English
    Publishing date 2023-12-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics16010017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mycophenolic Acid Exposure Determines Antibody Formation Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study.

    Meziyerh, Soufian / Bouwmans, Pim / van Gelder, Teun / van der Helm, Danny / Messchendorp, Lianne / van der Boog, Paul J M / de Fijter, Johan W / Moes, Dirk Jan A R / de Vries, Aiko P J

    Clinical pharmacology and therapeutics

    2023  Volume 114, Issue 1, Page(s) 118–126

    Abstract: Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID-19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been ... ...

    Abstract Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID-19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been shown to affect antibody formation negatively and may be an important modifiable risk factor. We investigated the exposure-response relationship between mycophenolic acid 12-hour area under the curve (AUC
    MeSH term(s) Humans ; Antibodies ; Antibody Formation ; Cohort Studies ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Kidney Transplantation/adverse effects ; Mycophenolic Acid/adverse effects ; SARS-CoV-2 ; Vaccination
    Chemical Substances Antibodies ; COVID-19 Vaccines ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2023-03-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2872
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice.

    van den Broek, Dennis A J / Meziyerh, Soufian / Budde, Klemens / Lefaucheur, Carmen / Cozzi, Emanuele / Bertrand, Dominique / López Del Moral, Covadonga / Dorling, Anthony / Emonds, Marie-Paule / Naesens, Maarten / de Vries, Aiko P J

    Transplant international : official journal of the European Society for Organ Transplantation

    2023  Volume 36, Page(s) 11321

    Abstract: Solid phase immunoassays improved the detection and determination of the antigen-specificity of donor-specific antibodies (DSA) to human leukocyte antigens (HLA). The widespread use of SPI in kidney transplantation also introduced new clinical dilemmas, ... ...

    Abstract Solid phase immunoassays improved the detection and determination of the antigen-specificity of donor-specific antibodies (DSA) to human leukocyte antigens (HLA). The widespread use of SPI in kidney transplantation also introduced new clinical dilemmas, such as whether patients should be monitored for DSA pre- or post-transplantation. Pretransplant screening through SPI has become standard practice and DSA are readily determined in case of suspected rejection. However, DSA monitoring in recipients with stable graft function has not been universally established as standard of care. This may be related to uncertainty regarding the clinical utility of DSA monitoring as a screening tool. This consensus report aims to appraise the clinical utility of DSA monitoring in recipients without overt signs of graft dysfunction, using the Wilson & Junger criteria for assessing the validity of a screening practice. To assess the evidence on DSA monitoring, the European Society for Organ Transplantation (ESOT) convened a dedicated workgroup, comprised of experts in transplantation nephrology and immunology, to review relevant literature. Guidelines and statements were developed during a consensus conference by Delphi methodology that took place in person in November 2022 in Prague. The findings and recommendations of the workgroup on subclinical DSA monitoring are presented in this article.
    MeSH term(s) Humans ; Kidney Transplantation ; Graft Rejection ; Isoantibodies ; Kidney ; Organ Transplantation ; HLA Antigens ; Graft Survival ; Transplant Recipients ; Tissue Donors ; Histocompatibility Testing ; Retrospective Studies
    Chemical Substances Isoantibodies ; HLA Antigens
    Language English
    Publishing date 2023-07-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.3389/ti.2023.11321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.

    Bezstarosti, Suzanne / Meziyerh, Soufian / Reinders, Marlies E J / Voogt-Bakker, Kim / Groeneweg, Koen E / Roelen, Dave L / Kers, Jesper / de Fijter, Johan W / Heidt, Sebastiaan

    HLA

    2023  Volume 102, Issue 1, Page(s) 3–12

    Abstract: Recently, the randomized phase-II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub-study analyzed formation of de novo donor- ... ...

    Abstract Recently, the randomized phase-II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub-study analyzed formation of de novo donor-specific HLA antibodies (dnDSA) in the context of the degree of HLA eplet mismatches. At the time of protocol biopsy at 6 months, 7/29 patients (24%) in the MSC group and 1/27 patient (3.7%) in the control group had developed dnDSA. In the MSC group, all dnDSA were anti-HLA-DQ; two patients had anti-DQ alone and five patients combined with anti-class I, HLA-DR or -DP. Despite excess dnDSA formation in the MSC-arm of the study, the evolution of eGFR (CKD-EPI) and proteinuria were comparable 2 years posttransplant. All dnDSA were complement-binding and three patients had antibody-mediated rejection in the protocol biopsy, but overall rejection episodes were not increased. Everolimus had to be discontinued in nine patients because of toxicity, and tacrolimus was reintroduced in six patients because of dnDSA formation. The HLA-DQ eplet mismatch load independently associated with dnDSA (adjusted hazard ratio = 1.07 per eplet mismatch, p = 0.008). A threshold of ≥11 HLA-DQ eplet mismatches predicted subsequent dnDSA in all 11 patients in the MSC group, but specificity was low (44%). Further research is warranted to explore HLA molecular mismatch load as a biomarker to guide personalized maintenance immunosuppression in kidney transplantation.
    MeSH term(s) Humans ; Kidney Transplantation/adverse effects ; Tacrolimus/therapeutic use ; Antibody Formation ; Graft Rejection ; Histocompatibility Testing/methods ; Alleles ; Antibodies ; HLA Antigens/genetics
    Chemical Substances Tacrolimus (WM0HAQ4WNM) ; Antibodies ; HLA Antigens
    Language English
    Publishing date 2023-03-03
    Publishing country England
    Document type Clinical Trial, Phase II ; Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2845111-9
    ISSN 2059-2310 ; 2059-2302
    ISSN (online) 2059-2310
    ISSN 2059-2302
    DOI 10.1111/tan.15008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.

    van den Born, Joost C / Meziyerh, Soufian / Vart, Priya / Bakker, Stephan J L / Berger, Stefan P / Florquin, Sandrine / de Fijter, Johan W / Gomes-Neto, António W / Idu, Mirza M / Pol, Robert A / Roelen, Dave L / van Sandwijk, Marit S / de Vries, Dorottya K / de Vries, Aiko P J / Bemelman, Frederike J / Sanders, Jan Stephan F

    Transplantation

    2024  Volume 108, Issue 2, Page(s) 556–566

    Abstract: Background: Evidence on the optimal maintenance of immunosuppressive regimen in kidney transplantation recipients is limited.: Methods: The Amsterdam, LEiden, GROningen trial is a randomized, multicenter, investigator-driven, noninferiority, open- ... ...

    Abstract Background: Evidence on the optimal maintenance of immunosuppressive regimen in kidney transplantation recipients is limited.
    Methods: The Amsterdam, LEiden, GROningen trial is a randomized, multicenter, investigator-driven, noninferiority, open-label trial in de novo kidney transplant recipients, in which 2 immunosuppression minimization strategies were compared with standard immunosuppression with basiliximab, corticosteroids, tacrolimus, and mycophenolic acid. In the minimization groups, either steroids were withdrawn from day 3, or tacrolimus exposure was reduced from 6 mo after transplantation. The primary endpoint was kidney transplant function at 24 mo.
    Results: A total of 295 participants were included in the intention-to-treat analysis. Noninferiority was shown for the primary endpoint; estimated glomerular filtration rate at 24 mo was 45.3 mL/min/1.73 m 2 in the early steroid withdrawal group, 49.0 mL/min/1.73 m 2 in the standard immunosuppression group, and 44.7 mL/min/1.73 m 2 in the tacrolimus minimization group. Participants in the early steroid withdrawal group were significantly more often treated for rejection ( P = 0.04). However, in this group, the number of participants with diabetes mellitus during follow-up and total cholesterol at 24 mo were significantly lower.
    Conclusions: Tacrolimus minimization can be considered in kidney transplant recipients who do not have an increased immunological risk. Before withdrawing steroids the risk of rejection should be weighed against the potential metabolic advantages.
    MeSH term(s) Humans ; Tacrolimus/adverse effects ; Kidney Transplantation/adverse effects ; Immunosuppressive Agents/adverse effects ; Immunosuppression Therapy ; Mycophenolic Acid/adverse effects ; Steroids ; Graft Rejection/prevention & control ; Carbazoles ; Tryptamines
    Chemical Substances Tacrolimus (WM0HAQ4WNM) ; frovatriptan (H82Q2D5WA7) ; Immunosuppressive Agents ; Mycophenolic Acid (HU9DX48N0T) ; Steroids ; Carbazoles ; Tryptamines
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Journal Article
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004776
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: The Clinical Impact of the C

    van Gelder, Teun / Meziyerh, Soufian / Swen, Jesse J / de Vries, Aiko P J / Moes, Dirk Jan A R

    Frontiers in pharmacology

    2020  Volume 11, Page(s) 1142

    Abstract: Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers ...

    Abstract Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers to reach the target concentration. CYP3A5 expressers can be considered fast metabolizers. The trough concentration/dose (C
    Language English
    Publishing date 2020-07-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2020.01142
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top